Evidence map›Paper›PMID 40622540›Full record

ReviewAdvances in experimental medicine and biology2025

Pattern Recognition by NOD-Like Receptors.

Timo-Daniel Voss, Lucy Hezinger, Thomas A Kufer

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Timo-Daniel VossUniversity of Hohenheim, Institute for Nutritional Medicine, Department of Immunology, Stuttgart, Germany. timodaniel.voss@uni-hohenheim.de.
Lucy HezingerUniversity of Hohenheim, Institute for Nutritional Medicine, Department of Immunology, Stuttgart, Germany.
Thomas A KuferUniversity of Hohenheim, Institute for Nutritional Medicine, Department of Immunology, Stuttgart, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nucleotide-binding oligomerization domain-like receptors (NLRs) are a family of cytosolic pattern recognition receptors (PRRs) and able to respond to conserved microbe-associated molecular patterns (MAMPs) and endogenous damage-associated molecular patterns (DAMPs). NLRs modulate the inflammatory response via multiple pathways including nuclear factor kappa-light chain-enhancer of activated B cells (NF-κB)-activation, mitogen-activated protein kinase (MAPK)-pathways and both canonical and non-canonical inflammasome formation. The latter results in auto-processing of caspase-1 and subsequent maturation of the cytokines interleukin 1 beta (IL-1β) and IL-18 as well as induction of pyroptosis by cleavage of gasdermin D (GSDMD) that induces pores in the cell membrane. NLRs act in synergy with other PRRs but some NLRs directly modulate adaptive immunity via transcriptional regulation of major histocompatibility complex (MHC) class I and class II. NLRs have an essential role as intracellular PRRs and thereby orchestrate inflammatory responses. NLR mutations and subsequent dysfunction can result in cancer or autoinflammatory diseases, such as Crohn's disease and ulcerative colitis, and many more, indicating their important role in classical immune recognition, maintenance of tissue homeostasis and reproductive functions. Here, we discuss our current understanding of mammalian NLRs that act as PRRs.

Indexed as

NLR ProteinsReceptors, Pattern RecognitionAnimalsHumansImmunity, InnateInflammasomesInflammationSignal TransductionInflammasomesNLR ProteinsReceptors, Pattern RecognitionDamage-associated molecular patternsDAMPMAMPMicrobe-associated molecular patternsNLRNOD-like receptorsPattern recognition receptorsPRR

Identifiers

PMID40622540

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.